Détail du document
Identifiant
oai:HAL:hal-03261732v1
Sujet
[SDV.NEU.NB]Life Sciences [q-bio]/...Auteur
Devos, David Hirsch, Etienne Wyse, RichardLangue
frEditeur
HAL CCSD;Wiley
Catégorie
CNRS - Centre national de la recherche scientifique
Année
2021
Date de référencement
15/12/2023
Mots clés
parkinsonRésumé
Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system.
Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials.
Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value.
© 2020 International Parkinson and Movement Disorder Society
Devos, David,Hirsch, Etienne,Wyse, Richard, 2021, Seven Solutions for Neuroprotection in Parkinson's Disease, HAL CCSD;Wiley
